Cargando…

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects

AIMS: This study evaluated the effects of sitaxentan on the pharmacodynamic [systemic blood pressure (BP)] and pharmacokinetic (PK) parameters of sildenafil in healthy volunteers. METHODS: Healthy subjects (18–60 years, n= 24) were randomized into two sequence groups. Group 1 received sitaxentan sod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stavros, Fiona, Kramer, William G, Wilkins, Martin R
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Science Inc 2010
Materias:	Pharmacokinetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805874/ https://www.ncbi.nlm.nih.gov/pubmed/20078609 http://dx.doi.org/10.1111/j.1365-2125.2009.03541.x

Ejemplares similares

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
por: van der Aar, Ellen, et al.
Publicado: (2019)

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
por: Shi, Rong, et al.
Publicado: (2016)

Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects
por: Kawaguchi, Nao, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
por: Allen, Ann, et al.
Publicado: (2014)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

Metabolism, Excretion, and Pharmacokinetics of [(14)C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
por: Miyazaki, Shiro, et al.
Publicado: (2019)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of a Long-Acting α-MSH Analog in Healthy Overweight and Obese Subjects
por: Royalty, Jane E, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
por: Krishna, Rajesh, et al.
Publicado: (2016)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Safety, pharmacokinetics, and pharmacodynamics of TV-1380, a novel mutated butyrylcholinesterase treatment for cocaine addiction, after single and multiple intramuscular injections in healthy subjects
por: Cohen-Barak, Orit, et al.
Publicado: (2015)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti‐CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases
por: Schwabe, Christian, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Single‐dose pharmacokinetics of co‐crystal of tramadol–celecoxib: Results of a four‐way randomized open‐label phase I clinical trial in healthy subjects
por: Videla, Sebastián, et al.
Publicado: (2017)

Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
por: Namour, Florence, et al.
Publicado: (2016)

Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment
por: Watanabe, Akiko, et al.
Publicado: (2021)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers
por: Pratt, Raymond D., et al.
Publicado: (2016)

A Randomized, Single‐Center, Double‐Blind, Placebo‐Controlled Multiple‐Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Imarikiren in Healthy Adult Nonelderly and Elderly Male Subjects
por: Matsuno, Kumi, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler
por: Breuer, C., et al.
Publicado: (2013)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

A phase‐1, open‐label, single‐dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment
por: Csonka, Denes, et al.
Publicado: (2016)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease
por: Hohlfeld, JM, et al.
Publicado: (2014)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers*
por: Zecca, Ernesto, et al.
Publicado: (2015)

Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence
por: El-Gaml, Rasha M., et al.
Publicado: (2022)

Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation
por: Kloprogge, Frank, et al.
Publicado: (2015)

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia
por: Xiao, Alan J., et al.
Publicado: (2016)

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants
por: Tzanis, Evan, et al.
Publicado: (2016)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
por: Zhai, John, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA
por: Abdallah, Hisham, et al.
Publicado: (2016)

The effect of dipyridamole on the pharmacokinetics of metformin: a randomized crossover study in healthy volunteers
por: El Messaoudi, S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b0u2h3tjdadkjkd6dv1vl3tb7e